Publications (241) JUAN JOSÉ LAHUERTA PALACIOS publications

filter_list

2026

  1. A critical analysis of the IMWG multiple myeloma complete response criterion in the era of mass spectrometry

    HemaSphere

  2. BLOOD-BASED RISK STRATIFICATION OF MYELOMA PATIENTS USING CIRCULATING TUMOR CELLS: RESULTS FROM THE EUROPEAN CTC CONSORTIUM

    Haematologica, Vol. 111

  3. Immune biomarkers of increased infection risk in multiple myeloma

    Blood, Vol. 147, Núm. 18, pp. 2081-2088

  4. Real-world evidence of measurable residual disease assessment in multiple myeloma

    Blood Advances, Vol. 10, Núm. 5, pp. 1559-1563

2025

  1. Clinical significance of complete remission and measurable residual disease in relapsed/refractory multiple myeloma patients treated with T-cell redirecting immunotherapy

    American Journal of Hematology, Vol. 100, Núm. 1, pp. 93-102

  2. High-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trial

    Blood, Vol. 146, Núm. 15, pp. 1747-1758

  3. High-risk features of early relapse in newly-diagnosed multiple myeloma: The impact of cytogenetics and response to initial therapy

    HemaSphere, Vol. 9, Núm. 4

  4. Induction therapy with bortezomib, melphalan, and prednisone followed by lenalidomide and dexamethasone versus carfilzomib, lenalidomide, and dexamethasone with or without daratumumab in older, fit patients with newly diagnosed multiple myeloma (GEM-2017FIT): a phase 3, open-label, multicentre, randomised clinical trial

    The Lancet Haematology, Vol. 12, Núm. 8, pp. e588-e598

  5. Is t(11;14) Always a Standard-Risk Cytogenetic Abnormality? Results From GEM05MENOS65 and GEM2012 PETHEMA/GEM Transplantation Trials

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 25, Núm. 7, pp. 494-504

  6. Minimally Invasive Assessment of Peripheral Residual Disease during Maintenance or Observation in Transplant-Eligible Patients with Multiple Myeloma

    Journal of Clinical Oncology, Vol. 43, Núm. 2, pp. 125-132

  7. Ultrasensitive detection of circulating multiple myeloma cells by next-generation flow after immunomagnetic enrichment

    Blood, Vol. 146, Núm. 8, pp. 964-970

2024

  1. A Simple Frailty Score Predicts Survival and Early Mortality in Systemic AL Amyloidosis

    Cancers, Vol. 16, Núm. 9

  2. Against realism: The politics of Salvador Dalí’s Christ of Saint John of the Cross

    Res: Anthropology and Aesthetics, Vol. 81-82, Núm. 1, pp. 212-228

  3. Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance

    Journal of Clinical Oncology, Vol. 42, Núm. 27, pp. 3247-3256

  4. Expression profile of Bcl-2 family proteins in newly diagnosed multiple myeloma patients

    HemaSphere, Vol. 8, Núm. 12

  5. High-risk cytogenetic abnormalities in multiple myeloma: PETHEMA-GEM experience

    HemaSphere, Vol. 8, Núm. 12

  6. Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease

    Annals of Hematology, Vol. 103, Núm. 12, pp. 5651-5661

  7. Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myeloma

    Blood, Vol. 144, Núm. 23, pp. 2432-2438

  8. Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma

    Blood, Vol. 143, Núm. 7, pp. 597-603

  9. Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection

    Haematologica, Vol. 109, Núm. 6, pp. 1909-1917